Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)
Condition: Type 2 Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Intervention: insulin glargine; metformin; acarbose; lifestyle therapy; insulin glargine; metformin; acarbose; lifestyle therapy; Standard glycemic care
Intervention description: sc injection; oral administration; oral administration; diet and exercise; sc injection; oral administration; oral administration; diet and exercise; as informed by the current clinical practice guidelines
Intervention MeSH terms: Insulin; Insulin, Globin Zinc; Metformin; Insulin Glargine; Acarbose
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 83.0
Sex: All
Minimum age: 30 Years
Maximum age: 80 Years
Healthy volunteers: No
Keywords: Diabetes; Insulin; Glargine; Metformin; Acarbose; Diet; Exercise; Lifestyle

Summary:

      The purpose of this pilot trial is to determine whether an intensive treatment with insulin
      glargine, metformin, acarbose and lifestyle can normalize blood glucose levels in patients
      with recently diagnosed type 2 diabetes mellitus when compared to standard diabetes care.
    

Eligibility criteria:

        Inclusion Criteria:

          1. men and women 30-80 years of age inclusive

          2. type 2 diabetes mellitus diagnosed by a physician within 3 years prior to patient
             enrollment

          3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks
             prior to screening and randomization

          4. HbA1C ≤ 8.5% on no oral hypoglycemic agents or HbA1C ≤ 7.5% on 1 agent or on
             half-maximal doses of 2 agents

          5. body mass index ≥ 23 kg/m2

          6. a negative pregnancy test and an agreement to use a reliable method of birth control
             for the duration of the trial in all females with childbearing potential

          7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG)

          8. ability and willingness to self-inject insulin

          9. provision of informed consent.

        Exclusion Criteria:

          1. current use of insulin therapy

          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance

          3. renal dysfunction as evidenced by serum creatinine (Cr) ≥ 124 μmol/l

          4. history of lactic acidosis or diabetic ketoacidosis

          5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper
             limit of normal at the time of enrollment

          6. history of inflammatory bowel disease, colonic ulcers, recent or significant bowel
             surgery, or predisposition to bowel obstruction

          7. cardiovascular disease including any of:

               -  systolic blood pressure >180 mmHg or diastolic blood pressure >105 mmHg

               -  peripheral vascular disease

               -  left bundle branch block or third degree AV block

               -  tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate

               -  stenotic valvular heart disease

               -  cardiomyopathy

               -  history of heart failure

               -  history of aortic dissection

               -  documented history of angina or coronary artery disease

               -  history of stroke or transient ischemic attack

          8. pulmonary disease with dependence on oxygen

          9. history of any disease requiring intermittent or continuous systemic glucocorticoid
             treatment

         10. history of any major illness with a life expectancy of <3 years

         11. history of injury or any other condition that significantly limits participant's
             ability to achieve moderate levels of physical activity

         12. any history of excessive alcohol intake, acute or chronic

         13. known hypersensitivity to metformin, acarbose, or insulin glargine.